Neuropsychiatric Manifestations of Thyroid Disease

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 3, 2013, Pages 453-476

  Feldman, Anna Z ^a   Shrestha, Rupendra T ^b   Hennessey, James V ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Hyperthyroidism; Hypothyroidism; Neuropsychiatric symptoms; Thyrotoxicosis

Indexed keywords

ANTIDEPRESSANT AGENT; LEVOTHYROXINE; LIOTHYRONINE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROTROPIN; THYROXINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DYSPHORIA; EUTHYROIDISM; HORMONE ACTION; HORMONE TRANSPORT; HUMAN; HYPOTHYROIDISM; IATROGENIC DISEASE; INTELLECTUAL IMPAIRMENT; MAJOR DEPRESSION; MANIA; MENTAL INSTABILITY; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; THYROID DISEASE; THYROTOXICOSIS;

HYPERTHYROIDISM; HYPOTHYROIDISM; NEUROPSYCHIATRIC SYMPTOMS; THYROTOXICOSIS;

HUMANS; HYPERTHYROIDISM; HYPOTHYROIDISM; MENTAL DISORDERS; THYROID HORMONES;

EID: 84883503757     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.05.005     Document Type: Review

References (170)

1. Report on myxoedema. Vol Suppl 1. Transactions of the Clinical Society of London. 1888.
2. Asher R. Myxoedematous madness. Br Med J 1949, 22:555-562.
3. Whybrow P.C. The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorders. Acta Med Austriaca 1994, 21:47-52.
4. Pollock M.A., Sturrock A., Marshall K., et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomized double blind placebo controlled crossover trial. BMJ 2001, 323(7318):891-895.
5. Sawka A.M., Gerstein H.C., Marriott M.J., et al. Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. JClin Endocrinol Metab 2003, 88(10):4551-4555.
6. Canaris G.J., Manowitz N.R., Mayor G.H., et al. The Colorado Thyroid Disease Prevalence Study. Arch Intern Med 2000, 160(4):526-534.
7. Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Survey (NHANES III). JClin Endocrinol Metab 2002, 87:489-499.
8. Boucai L., Surks M.I. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol (Oxf) 2009, 70(5):788-793.
9. Boucai L., Hollowell J.G., Surks M.I. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid 2011, 21(1):5-11.
10. Panicker V., Evans J., Bjoro T., et al. Aparadoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol (Oxf) 2009, 71(4):574-580.
11. Burger A.G. Is there a place for a combined treatment of athyreotic patients with thyroxine and triiodothyronine?. Clin Thyroidal 2012, 24(2):2-4.
12. Papakostas G.I., Cooper-Kazaz R., Appelhof B.C., et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 2009, 24(1):19-25.
13. Surks M.I., Hollowell J.G. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. JClin Endocrinol Metab 2007, 92(12):4575-4582.
14. Waring A.C., Arnold A.M., Newman A.B., et al. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. JClin Endocrinol Metab 2012, 97(11):3944-3950.
15. Atzmon G., Barzilai N., Hollowell J.G., et al. Extreme longevity is associated with increased serum thyrotropin. JClin Endocrinol Metab 2009, 94(4):1251-1254.
16. Bauer M., Szuba M.P., Whybrow P.C. Assessment of thyroid function. Psychoneuroendocrinology: the scientific basis of clinical practice 2003, vol. 1:366-399. American Psychiatric Publishing Inc, Washington, DC. 1st edition.
17. Atzmon G., Barzilai N., Surks M.I., et al. Genetic predisposition to elevated serum thyrotropin is associated with exceptional longevity. JClin Endocrinol Metab 2009, 94(12):4768-4775.
18. Howland R.H. Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment. JClin Psychiatry 1993, 54(2):47-54.
19. Hennessey J.V., Jackson I.M. The interface between thyroid hormones and psychiatry. Endocrinologist 1996, 6:214-223.
20. Stern R.A., Robinson B., Thorner A.R., et al. Asurvey study of neuropsychiatric complaints in patients with Graves' disease. JNeuropsychiatry Clin Neurosci 1996, 8(2):181-185.
21. Bommer M., Eversmann T., Pickardt R., et al. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin Wochenschr 1990, 68(11):552-558.
22. Stoudemire A. Psychological factors affecting medical conditions. Kaplan and Sadock's comprehensive textbook of psychiatry; No. II 2000, Lippincott Williams and Wilkins, Philadelphia. B.J. Sadock, V. Sadock (Eds.).
23. Sait Gonen M., Kisakol G., Savas Cilli A., et al. Assessment of anxiety in subclinical thyroid disorders. Endocr J 2004, 51(3):311-315.
24. Kalmijn S., Mehta K.M., Pols H.A., et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf) 2000, 53(6):733-737.
25. van der Cammen T.J., Mattace-Raso F., van Harskamp F., et al. Lack of association between thyroid disorders and Alzheimer's disease in older persons: a cross-sectional observational study in a geriatric outpatient population. JAm Geriatr Soc 2003, 51(6):884.
26. Franklyn J.A. The thyroid-too much and too little across the ages. The consequences of subclinical thyroid dysfunction. Clin Endocrinol (Oxf) 2013, 78(1):1-8.
27. Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004, 291(2):228-238.
28. Sawin C.T. Thyroid disease in older persons. Diseases of the thyroid 2010, 95. Humana Press, Totowa (NJ). 2nd edition. L. Braverman (Ed.).
29. Meurisse M., Preudhomme L., Lamberty G., et al. Iatrogenic thyrotoxicosis. Causal circumstances, pathophysiology and principles of treatment. Review of the literature. Acta Chir Belg 2001, 101(6):257-266.
30. Chopra I.J., Solomon D.H., Huang T.S. Serum thyrotropin in hospitalized psychiatric patients: evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay. Metabolism 1990, 39(5):538-543.
31. Hein M.D., Jackson I.M. Thyroid function in psychiatric illness. Gen Hosp Psychiatry 1990, 12:232-244.
32. Carta M.G., Loviselli A., Hardoy M.C., et al. The link between thyroid autoimmunity (antithyroid peroxidase autoantibodies) with anxiety and mood disorders in the community: a field of interest for public health in the future. BMC Psychiatry 2004, 4:25.
33. Fava M., Labbate L.A., Abraham M.E., et al. Hypothyroidism and hyperthyroidism in major depression revisited. JClin Psychiatry 1995, 56(5):186-192.
34. Salvador J., Dieguez C., Scanlon M.F. The circadian rhythms of thyrotropin and prolactin secretion. Chronobiol Int 1988, 5:85-93.
35. Souetre E., Salvati E., Wehr T.A., et al. Twenty-four hour profiles of body temperature and plasma TSH in bipolar patients during depression and during remission and normal control subjects. Am J Psychiatry 1988, 145:1133-1137.
36. Kasper S., Sack D.A., Wehr T.A., et al. Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression. Biol Psychiatry 1988, 24:631-641.
37. Bianco A.C., Salvatore D., Gereben B., et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002, 23(1):38-89.
38. Gereben B., Zavacki A.M., Ribich S., et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 2008, 29(7):898-938.
39. Mentuccia D., Proietti-Pannunzi L., Tanner K., et al. Association between a novelvariant of the human type 2 deiodinase gene Thr92Ala and insulin resistance:evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002, 51(3):880-883.
40. Appelhof B.C., Peeters R.P., Wiersinga W.M., et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy. JClin Endocrinol Metab 2005, 90(11):6296-6299.
41. Panicker V., Saravanan P., Vaidya B., et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. JClin Endocrinol Metab 2009, 94(5):1623-1629.
42. Cleare A.J., McGregor A., O'Keane V. Neuroendocrine evidence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxf) 1995, 43(6):713-719.
43. Bauer M., Whybrow P.C. Thyroid hormones and the central nervous system in affective illness: interactions that may have clinical significance. Integr Psychiatry 1988, 6:75-100.
44. Joffe R.T. Aperspective on the thyroid and depression. Can J Psychiatry 1990, 35(9):754-758.
45. Jackson I.M. The thyroid axis and depression. Thyroid 1998, 8(10):951-956.
46. Hage M.P., Azar S.T. The link between thyroid function and depression. JThyroid Res 2012, 2012:590648.
47. van der Deure W.M., Appelhof B.C., Peeters R.P., et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf) 2008, 69(5):804-811.
48. Constant E.L., de Volder A.G., Ivanoiu A., et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. JClin Endocrinol Metab 2001, 86(8):3864-3870.
49. Kinuya S., Michigishi T., Tonami N., et al. Reversible cerebral hypoperfusion observed with Tc-99m HMPAO SPECT in reversible dementia caused by hypothyroidism. Clin Nucl Med 1999, 24(9):666-668.
50. Forchetti C.M., Katsamakis G., Garron D.C. Autoimmune thyroiditis and a rapidly progressive dementia: global hypoperfusion on SPECT scanning suggests a possible mechanism. Neurology 1997, 49(2):623-626.
51. Krausz Y., Freedman N., Lester H., et al. Regional cerebral blood flow in patients with mild hypothyroidism. JNucl Med 2004, 45(10):1712-1715.
52. Bauer M., Silverman D.H., Schlagenhauf F., et al. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy. JClin Endocrinol Metab 2009, 94(8):2922-2929.
53. Canaris G.J., Steiner J.F., Ridgway E.C. Do traditional symptoms of hypothyroidism correlate with biochemical disease?. JGen Intern Med 1997, 12(9):544-550.
54. van de Ven A.C., Netea-Maier R.T., de Vegt F., et al. Is there a relationship between fatigue perception and the serum levels of thyrotropin and free thyroxine in euthyroid subjects?. Thyroid 2012, 22(12):1236-1243.
55. Garber J.R., Cobin R.H., Gharib H., et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012, 22(12):1200-1235.
56. Gharib H., Tuttle R.M., Baskin H.J., et al. Consensus statement: subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endcrinologists, the American Thyroid Association, and The Endocrine Society. JClin Endocrinol Metab 2005, 90(1):581-585.
57. Jain V.K. Apsychiatric study of hypothyroidism. Psychiatr Clin (Basel) 1972, 5(2):121-130.
58. Schuff K., Samuels M.H., Whybrow P., et al. Psychiatric and cognitive effects of hypothyroidism. The thyroid a fundamental and clinical text 2013, vol. 1:596-599. Lippincott Williams and Wilkins, Philadelphia. 10th edition.
59. Hall R.C. Psychiatric effects of thyroid hormone disturbance. Psychosomatics 1983, 24(1):7-11. 15-8.
60. Heinrich T.W., Grahm G. Hypothyroidism presenting as psychosis: myxedema madness revisited. Prim Care Companion J Clin Psychiatry 2003, 5(6):260-266.
61. Madakasira S., Hall T.B. Capgras syndrome in a patient with myxedema. Am J Psychiatry 1981, 138(11):1506-1508.
62. Azzopardi L., Murfin C., Sharda A., et al. Myxoedema madness. BMJ Case Rep 2010, 2010. pii:bcr0320102841.
63. Davis J.D., Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol 2007, 32(1):49-65.
64. Gulseren S., Gulseren L., Hekimsoy Z., et al. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res 2006, 37(1):133-139.
65. Jonklaas J., Davidson B., Bhagat S., et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 2008, 299(7):769-777.
66. Boeving A., Paz-Filho G., Radominski R.B., et al. Low-normal or high-normal thyrotropin target levels during treatment of hypothyroidism: a prospective, comparative study. Thyroid 2011, 21(4):355-360.
67. Walsh J.P., Ward L.C., Burke V., et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. JClin Endocrinol Metab 2006, 91(7):2624-2630.
68. Saravanan P., Chau W.F., Roberts N., et al. Psychological well-being in patients on "adequate" doses of L-thyroxine: Results of a large, controlled community-based questionnaire study. Clin Endocrinol 2002, 57:577-585.
69. Edwards C.M., Cox J.P., Robinson S. Psychological well-being of patients on L-thyroxine. Clin Endocrinol (Oxf) 2003, 59(2):264-265.
70. Wekking E.M., Appelhof B.C., Fliers E., et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005, 153(6):747-753.
71. Murray G.R. Note on the treatment of myxoedema by hypodermic injections of an extract of the thyroid gland of a sheep. Br Med J 1891, 2(1606):796-797.
72. Selenkow H.A., Wool M.S. Anew synthetic thyroid hormone combination for clinical therapy. Ann Intern Med 1967, 67(1):90-99.
73. Sachs B.A., Wolfman L., Murthy G. Lipid and clinical response to a new thyroid hormone combination. Am J Med Sci 1968, 256(4):232-238.
74. Taylor S., Kapur M., Adie R. Combined thyroxine and triiodothyronine for thyroid replacement therapy. Br Med J 1970, 2(5704):270-271.
75. Brent G.A., Larsen P.R. Treatment of hypothyroidism. Werner and Ingbar's the thyroid: a fundamental and clinical text 2000, 853-860. Lippincott Williams and Wilkins, Philadelphia. 8th edition. L.E. Braverman, R.D. Utiger (Eds.).
76. Hennessey J.V., Evaul J.E., Tseng Y.C., et al. L-thyroxine dosage: a reevaluation of therapy with contemporary preparations. Ann Intern Med 1986, 105:11-15.
77. Samuels M.H., Schuff K.G., Carlson N.E., et al. Health status, mood, and cognition in experimentally induced subclinical hypothyroidism. JClin Endocrinol Metab 2007, 92(7):2545-2551.
78. Bunevicius R., Kazanavicius G., Zalinkevicius R., et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. NEngl J Med 1999, 340:424-429.
79. Bunevicius R., Prange A.J. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol 2000, 3(2):167-174.
80. Walsh J.P., Shiels L., Lim E.M., et al. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. JClin Endocrinol Metab 2003, 88(10):4543-4550.
81. Grozinsky-Glasberg S., Fraser A., Nahshoni E., et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. JClin Endocrinol Metab 2006, 91(7):2592-2599.
82. McDermott M.T. Does combination T4 and T3 therapy make sense?. Endocr Pract 2012, 18(5):750-757.
83. Gharib H., Tuttle R.M., Baskin H.J., et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Endocr Pract 2004, 10(6):497-501.
84. Vanderpump M. Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism. JClin Endocrinol Metab 2007, 92(6):2033-2035.
85. Parle J.V., Franklyn J.A., Cross K.W., et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) 1991, 34(1):77-83.
86. Somwaru L.L., Rariy C.M., Arnold A.M., et al. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. JClin Endocrinol Metab 2012, 97(6):1962-1969.
87. Huber G., Staub J.J., Meier C., et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. JClin Endocrinol Metab 2002, 87(7):3221-3226.
88. Stern R.A., Prange A.J. Neuropsychiatric aspects of endocrine disorders. Comprehensive textbook of psychiatry 1995, vol. 6:241-251. Williams and Wilkins, Baltimore (MD).
89. Cooper D.S., Halpern R., Wood L.C., et al. L-thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Intern Med 1984, 101(1):18-24.
90. Monzani F., DelGerra P., Caraccion N., et al. Subclinical hypothyroidism: neuro-behavioral features and beneficial effect of L-thyroxine treatment. Clin Investig 1993, 71:367-371.
91. Razvi S., Ingoe L., Keeka G., et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. JClin Endocrinol Metab 2007, 92(5):1715-1723.
92. Vigario P., Teixeira P., Reuters V., et al. Perceived health status of women with overt and subclinical hypothyroidism. Med Princ Pract 2009, 18(4):317-322.
93. Bell R.J., Rivera-Woll L., Davison S.L., et al. Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease-a community-based study. Clin Endocrinol 2007, 66(4):548-556.
94. Jorde R., Waterloo K., Storhaug H., et al. Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. JClin Endocrinol Metab 2006, 91(1):145-153.
95. Parle J., Roberts L., Wilson S., et al. Arandomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. JClin Endocrinol Metab 2010, 95(8):3623-3632.
96. Demartini B., Masu A., Scarone S., et al. Prevalence of depression in patients affected by subclinical hypothyroidism. Panminerva Med 2010, 52(4):277-282.
97. Roberts L.M., Pattison H., Roalfe A., et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction?. Ann Intern Med 2006, 145(8):573-581.
98. Almeida O.P., Alfonso H., Flicker L., et al. Thyroid hormones and depression: the Health in Men study. Am J Geriatr Psychiatry 2011, 19(9):763-770.
99. Joffe R.T., Pearce E.N., Hennessey J.V., et al. Subclinical hypothyroidism, mood, and cognition in older adults: a review. Int J Geriatr Psychiatry 2013, 28(2):111-118.
100. Tappy L., Randin J.P., Schwed P., et al. Prevalence of thyroid disorders in psychogeriatric inpatients. A possible relationship of hypothyroidism with neurotic depression but not with dementia. JAm Geriatr Soc 1987, 35(6):526-531.
101. Joffe R.T., Levitt A.J. Major depression and subclinical (grade 2) hypothyroidism. Psychoneuroendocrinology 1992, 17(2-3):215-221.
102. Osterweil D., Syndulko K., Cohen S.N., et al. Cognitive function in non-demented older adults with hypothyroidism. JAm Geriatr Soc 1992, 40(4):325-335.
103. Sanavi S., Afshar R. Subacute thyroiditis following ginger (Zingiber officinale) consumption. Int J Ayurveda Res 2010, 1(1):47-48.
104. Correia N., Mullally S., Cooke G., et al. Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. JClin Endocrinol Metab 2009, 94(10):3789-3797.
105. Zhu D.F., Wang Z.X., Zhang D.R., et al. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain 2006, 129(Pt11):2923-2930.
106. Aghili R., Khamseh M.E., Malek M., et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Arch Med Sci 2012, 8(6):1096-1101.
107. Yin J.J., Liao L.M., Luo D.X., et al. Spatial working memory impairment in subclinical hypothyroidism: an fMRI study. Neuroendocrinology 2013, 97(3):260-270.
108. Bauer M., Baur H., Berghofer A., et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. JAffect Disord 2002, 68(2-3):285-294.
109. Bauer M., Berghofer A., Bschor T., et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology 2002, 27(4):620-628.
110. Baethge C., Reischies F.M., Berghofer A., et al. Effects of supraphysiological doses of L-thyroxine on cognitive function in healthy individuals. Psychiatry Res 2002, 110(2):117-123.
111. Fava M. Augmentation and combination strategies in treatment-resistant depression. JClin Psychiatry 2001, 62(Suppl 18):4-11.
112. Cowen P.J. New drugs, old problems: revisiting. pharmacological management of treatment-resistant depression. Adv Psychiatr Treat 2005, 11:19-27.
113. Nemeroff C.B. Augmentation regimens for depression. JClin Psychiatry 1991, 52(Suppl):21-27.
114. Shelton R.C., Winn S., Ekhatore N., et al. The effects of antidepressants on the thyroid axis in depression. Biol Psychiatry 1993, 33(2):120-126.
115. Stern R.A., Nevels C.T., Shelhorse M.E., et al. Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: preliminary findings. Biol Psychiatry 1991, 30(6):623-627.
116. Nakamura T., Nomura J. Comparison of thyroid function between responders and nonresponders to thyroid hormone supplementation in depression. Jpn J Psychiatry Neurol 1992, 46(4):905-909.
117. Barak Y., Stein D., Levine J., et al. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: an open trial. Hum Psychopharmacol 1996, 11:463-467.
118. Lojko D., Rybakowski J.K. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. JAffect Disord 2007, 103(1-3):253-256.
119. Joffe R.T., Singer W. Acomparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990, 32(3):241-251.
120. Joffe R.T. Is the thyroid still important in major depression?. JPsychiatry Neurosci 2006, 31(6):367-368.
121. Prange A.J., Wilson I.C., Rabon A.M., et al. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969, 126:39-51.
122. Joffe R.T., Sokolov S.T., Singer W. Thyroid hormone treatment of depression. Thyroid 1995, 5:235-239.
123. Applehof B.C., Brouwer J.P., Van Dyck R., et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. JClin Endocrinol Metab 2004, 89(12):6271-6276.
124. Cooper-Kazaz R., Apter J.T., Cohen R., et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007, 64(6):679-688.
125. Posterank M., Novak S., Stern R.A., et al. Apilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol 2008, 11(1):15-25.
126. Bech P. Acute therapy of depression. JClin Psychiatry 1993, 54(Suppl):18-27. [discussion: 28].
127. Nelson J.C. Augmentation strategies in depression 2000. JClin Psychiatry 2000, 61(Suppl 1):13-19.
128. Ogura C., Okuma T., Uchida Y., et al. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatr Neurol Jpn 1974, 28(3):179-186.
129. Banki C.M. Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977, 11(4):311-315.
130. Goodwin F.K., Prange A.J., Post R.M., et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982, 139(1):34-38.
131. Schwarcz G., Halaris A., Baxter L., et al. Normal thyroid function in desipramine nonresponders converted to responders by the addition of L-triiodothyronine. Am J Psychiatry 1984, 141(12):1614-1616.
132. Gitlin M.J., Weiner H., Fairbanks L., et al. Failure of T3 to potentiate tricyclic antidepressant response. JAffect Disord 1987, 13:267-272.
133. Joffe R.T., Singer W., Levitt A.J., et al. Aplacebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993, 50:387-393.
134. Thase M.E., Kupfer D.J., Jarrett D.B. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. JClin Psychiatry 1989, 50(10):385-388.
135. Fliers E., Applehof B.C., Brouwer J.P., et al. Efficacy of triiodothyronine (T3) addition to paroxetine in major depressive disorder: a randomized clinical trial. Annual Meeting of the Endocrine Society 2003, The Endocrine Society, Philadelphia, S19-2, p. 25.
136. Tremont G., Stern R.A. Use of thyroid hormone to diminish the cognitive side effects of psychiatric treatment. Psychopharmacol Bull 1997, 33(2):273-280.
137. Cooper-Kazaz R., Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008, 11(5):685-699.
138. Cooper-Kazaz R., van der Deure W.M., Medici M., et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. JAffect Disord 2009, 116(1-2):113-116.
139. Kathol R.G., Delahunt J.W. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen Hosp Psychiatry 1986, 8(1):23-28.
140. Trzepacz P.T., McCue M., Klein I., et al. Apsychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry 1988, 10(1):49-55.
141. Rockey P.H., Griep R.J. Behavioral dysfunction in hyperthyroidism. Improvement with treatment. Arch Intern Med 1980, 140(9):1194-1197.
142. Burch E.A., Messervy T.W. Psychiatric symptoms in medical illness: hyperthyroidism revisited. Psychosomatics 1978, 19(2):71-75.
143. Taylor J.W. Depression in thyrotoxicosis. Am J Psychiatry 1975, 132(5):552-553.
144. Ozten E., Tufan A.E., Cerit C., et al. Delusional parasitosis with hyperthyroidism in an elderly woman: a case report. JMed Case Rep 2013, 7(1):17.
145. Lazarus A., Jaffe R. Resolution of thyroid-induced schizophreniform disorder following subtotal thyroidectomy: case report. Gen Hosp Psychiatry 1986, 8(1):29-31.
146. Brownlie B.E., Rae A.M., Walshe J.W., et al. Psychoses associated with thyrotoxicosis - 'thyrotoxic psychosis.' A report of 18 cases, with statistical analysis of incidence. Eur J Endocrinol 2000, 142(5):438-444.
147. Wartofsky L. Thyrotoxic storm. Werner and Ingbar's the thyroid: a fundamental and clinical text 2013, vol. 1:481-486. Lippincott Williams and Wilkins, Philadelphia. 10th edition.
148. Orenstein H., Peskind A., Raskind M.A. Thyroid disorders in female psychiatric patients with panic disorder or agoraphobia. Am J Psychiatry 1988, 145(11):1428-1430.
149. Suwalska A., Lacka K., Lojko D., et al. Quality of life, depressive symptoms and anxiety in hyperthyroid patients. Rocz Akad Med Bialymst 2005, 50(Suppl 1):61-63.
150. Bunevicius R., Velickiene D., Prange A.J. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease. Gen Hosp Psychiatry 2005, 27(2):133-139.
151. Lu C.L., Lee Y.C., Tsai S.J., et al. Psychiatric disturbances associated with hyperthyroidism: an analysis report of 30 cases. Zhonghua Yi Xue Za Zhi (Taipei) 1995, 56(6):393-398.
152. Fahrenfort J.J., Wilterdink A.M., van der Veen E.A. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology 2000, 25(2):201-211.
153. Marqusee E., Haden S.T., Utiger R.D. Subclinical thyrotoxicosis. Endocrinol Metab Clin North Am 1998, 27(1):37-49.
154. Hendrick V., Altshuler L., Whybrow P. Psychoneuroendocrinology of mood disorders. The hypothalamic-pituitary-thyroid axis. Psychiatr Clin North Am 1998, 21(2):277-292.
155. Biondi B., Palmieri E.A., Fazio S., et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. JClin Endocrinol Metab 2000, 85(12):4701-4705.
156. Bauer M., Samuels M.H., Whybrow P. Behavioral and psychiatric aspects of thyrotoxicosis. Werner and Ingbar's the thyroid: a fundamental and clinical text 2013, vol. 1:75-480. Lippincott, Williams and Wilkins, Philadelphia. 10th edition.
157. Cooper D.S. Subclinical thyroid disease: a clinician's perspective. Ann Intern Med 1998, 129(2):135-138.
158. Sgarbi J.A., Villaca F.G., Garbeline B., et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. JClin Endocrinol Metab 2003, 88(4):1672-1677.
159. Faber J., Jensen I.W., Petersen L., et al. Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998, 48(3):285-290.
160. Sarne D., DeGroot L.J. Effects of the environment, chemicals and drugs on thyroid function 2002, Endocrine Education, Inc, Available at:, Accessed July 9, 2013. http://www.thyroidmanager.org.
161. Ladenson P.W. Problems in management of hypothyroidism. Diseases of the thyroid 2010, 161-176. Humana Press, Totowa (NJ). 2nd edition. L.E. Braverman (Ed.).
162. Botella-Carretero J.I., Galan J.M., Caballero C., et al. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2003, 10(4):601-610.
163. Eustatia-Rutten C.F., Corssmit E.P., Pereira A.M., et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 2006, 64(3):284-291.
164. Husson O., Haak H.R., Oranje W.A., et al. Health-related quality of life among thyroid cancer survivors: a systematic review. Clin Endocrinol (Oxf) 2011, 75(4):544-554.
165. Rhee C.M., Bhan I., Alexander E.K., et al. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med 2012, 172(2):153-159.
166. Martin F.I., Tress B.W., Colman P.G., et al. Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 1993, 95(1):78-82.
167. Arlt S., Burkhardt D., Wiedemann K. Thyrotoxicosis after iodine contrast medium administration: rapid mood swing to mania and subsequent psychotic depression in a patient with bipolar disorder during lithium therapy. Pharmacopsychiatry 2008, 41(4):163-165.
168. Bogazzi F., Tomisti L., Bartalena L., et al. Amiodarone and the thyroid: a 2012 update. JEndocrinol Invest 2012, 35(3):340-348.
169. Hamnvik O.P., Larsen P.R., Marqusee E. Thyroid dysfunction from antineoplastic agents. JNatl Cancer Inst 2011, 103(21):1572-1587.
170. Ross D.S. Management of the various causes of thyrotoxicosis. Diseases of the thyroid 2010, 177-198. Humana Press, Totowa (NJ). 2nd edition. L.E. Braverman (Ed.).